Aflibercept

• A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8… Pending
  2025-524575-22-00 Phase II/III 1 country Eyebiotech Limited
• Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD Recruiting
  2025-523478-17-00 Phase IV 1 country Medical University Of Graz
• Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER). Recruiting
  2023-504751-28-00 Phase III 5 countries King's College Hospital NHS Foundation Trust; King's College London
• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting
  2025-523937-25-00 Phase III 3 countries Eyepoint Inc.
• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting
  2025-523938-10-00 Phase III 3 countries Eyepoint Inc.
• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting
  2025-522231-34-00 Phase III 6 countries Alvotech Swiss AG
• A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula… Recruiting
  2025-521349-25-00 Phase III 9 countries 4d Molecular Therapeutics Inc.
• Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting
  2024-519669-23-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Treatment of neovascular AMD: Artificial intelligence in real-world setting Recruiting
  2024-518482-99-01 Phase IV 1 country Medical University Of Vienna
• LUCIA: A Phase 3 randomized, double-masked study comparing the efficacy of EYP-1901 against aflibercept Ended
  2024-518030-83-00 Phase III 5 countries Eyepoint Inc.
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended
  2023-503666-23-00 Phase III 5 countries Abbvie Deutschland GmbH & Co. KG
• Extension Study to Evaluate the Long-Term Outcomes of Paediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe… Ended
  2024-513231-24-00 Phase III 2 countries Regeneron Pharmaceuticals Inc.
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
• The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With … Ended
  2023-506317-22-00 Phase II 1 country Vaestra Goetalandsregionen
• Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, si… Ended
  2024-515497-26-00 Phase III/IV 1 country Medical University Of Graz
• A study to learn about the blood levels of aflibercept when high-dose aflibercept is injected in both eyes of participants with diabetic mac… Ended
  2024-511665-11-00 Phase IV 3 countries Bayer AG
• Clinical study to evaluate the handling and safety of AVT06 PFS in subjects with chorioretinal vascular disease (ALVOEYE-D). Ended
  2023-505225-13-00 Phase III 1 country Alvotech Swiss AG
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 Phase III 14 countries Bayer AG
• Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked compar… Ended
  2024-515377-10-00 Phase III/IV 1 country Medical University Of Graz
• A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended
  2024-512880-30-00 Phase III 16 countries Opthea Limited
• Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated o… Ended
  2024-516681-10-01 Phase II 1 country Fondation A De Rothschild
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 Phase III 10 countries Bayer AG
• Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended
  2024-511885-35-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
• MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY … Ended
  2024-517362-41-00 Phase II 1 country Fondation Franc.Cancerologie Digestive

Showing 1–24 of 26 trials